倒计时2天 净利润从 2022 年的 2.21 亿元骤降至 2023 年得 1.19 亿元，跌幅近乎 50% ； 2024 年营收勉强触及 2022 年水平，归母净利润却仍停 留在 1.31 亿元，仅为巅峰时期的六成。 针对业绩的大幅跳水，福建德尔给出的解释是受 "行业周期"影响。" 2023 年新能源产品价格暴跌拖累扣非净利润，这是'行业共有因素'。" 福建德尔的新能源电池材料产品主要是六氟磷酸锂，用于生产锂离子电池电解液，最终主要应用于动力、储能等锂电池制造。 客户包括湖州 昆仑、天赐材料、杉杉股份、新宙邦、法恩莱特、亿恩科等。 产品端， 福建德尔 开发系列新型锂盐添加剂以及高性能阻燃添加剂、适宜极低温环境的高性能含氟溶剂等，在建项目包括二氟草酸硼酸锂、 二氟双草酸磷酸锂等新产品。 福建德尔拟建项目包括以双氟磺酰亚胺锂为代表的新型锂盐产品、以六氟磷酸钠为代表的钠盐添加剂、以电子级硫酸锰为代表的锰系新能源材 料、以碳纳米管电池阴极材料为代表的碳材料。 金钠科技总冠名-第八届起点钠电高峰论坛 活动主题： 全链条技术产能跃升 GWH级出货"真"元年 主办单位： 起点钠电、起点研究院（SPIR） 总冠名单位： 金 ...

专注含氟新材料领域的福建德尔IPO告终。 8月22日，上交所公告，因福建德尔科技股份有限公司(简称"福建德尔")及其保荐人撤回发行上市申请，根据有关规定，上交所终止其发行上市审核。 | 福建德尔科技股份有限公司 | | --- | | 公司全称 | 在湿电子化学品方面，报告期内福建德尔主要产品包括通用型半导体级湿电子化学品和TFT功能型混配试剂。福建德尔是国内少数能够生产集成电路制造用 高端半导体级湿电子化学品及TFT功能型混配试剂的企业之一。目前，公司已具备G5级电子级氢氟酸、电子级氨水、电子级双氧水和G4级电子级BOE/SIO 蚀刻液生产能力，产品品质达到国内同类先进水平。 截至2025年3月31日，福建德尔已获得授权的国内发明专利305项、国外发明专利6项。公司积极推进行业标准体系建立和完善，主导或参与制定国家标准9 项、行业标准1项、团体标准9项，逐步扩大公司在行业内的影响力。 业绩方面，2022年至2024年，福建德尔实现营收16.98亿元、14.18亿元和16.87亿元，净利润为2.21亿元、1.19亿元和1.31亿元。 回顾其上市历程，2023年6月福建德尔沪主板IPO获受理，公司原计划募资19 ...

Core Viewpoint - Del Technology, a fluorochemical company, is facing significant challenges as it prepares for its IPO, with declining profits and a reduced fundraising target, indicating a critical juncture in its business transformation [1][3][22]. Financial Performance - The company's net profit attributable to shareholders has declined for three consecutive years, from 303 million yuan in 2021 to 119 million yuan in 2023, with only 64.01 million yuan in the first half of 2024 [3][5]. - The adjusted net profit after excluding non-recurring gains and losses dropped from 184 million yuan in 2022 to 86 million yuan in 2024, a decline of over 50% [5]. - The total assets increased from 5.36 billion yuan in 2022 to 6.86 billion yuan in 2024, while the total revenue showed a decrease from 1.70 billion yuan in 2022 to 1.69 billion yuan in 2024 [6][20]. IPO and Fundraising - The IPO fundraising target has been significantly reduced from 3 billion yuan to 1.945 billion yuan, a decrease of 35% [4][9]. - The number of fundraising projects has been cut from seven to three, with all projects related to new energy materials removed [4][9]. Business Transformation - The company is shifting its focus towards semiconductor materials, with revenue from this segment exceeding 50% in the first half of 2024 [7]. - The reliance on lithium hexafluorophosphate, which previously accounted for 38% of revenue, has diminished, with its contribution dropping to 4.28% in 2024 [5][7]. Research and Development - The company's R&D expenditure ratio has been low, ranging from 1.84% to 2.24% from 2022 to 2024, significantly below the industry average of 5.11% to 5.46% [12][15]. - The company claims that the low R&D demand in its fluorochemical materials business justifies the reduced investment, but this raises concerns about its long-term technological competitiveness [12][15]. Governance Issues - The three actual controllers of the company hold only 35.06% of the shares, which may lead to control risks post-IPO due to further dilution of voting rights [16][17]. - Historical issues with shareholding representation have raised concerns about the clarity of ownership, particularly with recent shareholding changes before the IPO application [17][18]. Financial Anomalies - In 2023, despite a 16.52% decline in revenue, accounts receivable increased by 49.83%, raising questions about the reasonableness of revenue recognition [19]. - The gross profit margin has decreased from 29.75% in 2022 to 16.04% in 2024, indicating weakened profitability [19][20]. Market Outlook - The company’s IPO journey has faced multiple challenges, with its status shifting from "suspended" to "inquiry" after financial updates [22]. - The semiconductor materials market is expected to grow at an annual rate of over 15%, but the company’s performance remains highly dependent on the semiconductor industry cycle [8][24].